Pranlukast Antagonizes CD49f and Reduces Stemness in Triple-Negative Breast Cancer Cells.
Inés Velázquez-QuesadaAngel Jonathan Ruiz-MorenoDiana Casique-AguirreCharmina Aguirre-AlvaradoFabiola Cortés-MendozaMarisol de la Fuente-GranadaCarlos García-PérezSonia Mayra Perez-TapiaAliesha González-ArenasAldo Segura-CabreraMarco Antonio Velasco VelazquezPublished in: Drug design, development and therapy (2020)
Our results support the function of pranlukast as a CD49f antagonist that reduces the CSC population in triple-negative breast cancer cells. The pharmacokinetics and toxicology of this drug have already been established, rendering a potential adjuvant therapy for breast cancer patients.